TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SanBio Co ( (JP:4592) ) has issued an update.
SanBio Co., Ltd. has entered into a committed credit line agreement with Mizuho Bank, Ltd. to secure funds for the establishment of manufacturing, distribution, and marketing infrastructure for its product, AKUUGO® Suspension for Intracranial Implantation. This financial arrangement is part of the company’s strategy to support the anticipated approval changes for AKUUGO®, although it is expected to have a minor impact on the company’s earnings for the fiscal year ending January 2026.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on developing regenerative cell medicines. The company is primarily involved in creating treatments for central nervous system disorders, with a market focus on innovative therapies for neurological conditions.
YTD Price Performance: 350.07%
Average Trading Volume: 5,488,429
Technical Sentiment Signal: Buy
Current Market Cap: Yen243.4B
For an in-depth examination of 4592 stock, go to TipRanks’ Stock Analysis page.